Global Acute Ischemic Stroke Drugs Market Size, Status and Forecast 2019-2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Acute Ischemic Stroke Drugs Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Tablet
- 1.4.3 Capsule
- 1.4.4 Other
- 1.5 Market by Application
- 1.5.1 Global Acute Ischemic Stroke Drugs Market Share by Application (2019-2025)
- 1.5.2 Hospitals
- 1.5.3 Diagnostic Centers
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Acute Ischemic Stroke Drugs Market Size
- 2.2 Acute Ischemic Stroke Drugs Growth Trends by Regions
- 2.2.1 Acute Ischemic Stroke Drugs Market Size by Regions (2019-2025)
- 2.2.2 Acute Ischemic Stroke Drugs Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
- 3.1 Acute Ischemic Stroke Drugs Market Size by by Players
- 3.1.1 Global Acute Ischemic Stroke Drugs Revenue by by Players (2014-2019)
- 3.1.2 Global Acute Ischemic Stroke Drugs Revenue Market Share by by Players (2014-2019)
- 3.1.3 Global Acute Ischemic Stroke Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Acute Ischemic Stroke Drugs Key Players Head office and Area Served
- 3.3 Key Players Acute Ischemic Stroke Drugs Product/Solution/Service
- 3.4 Date of Enter into Acute Ischemic Stroke Drugs Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Acute Ischemic Stroke Drugs Market Size by Type (2014-2019)
- 4.2 Global Acute Ischemic Stroke Drugs Market Size by Application (2014-2019)
5 North America
- 5.1 North America Acute Ischemic Stroke Drugs Market Size (2014-2019)
- 5.2 Acute Ischemic Stroke Drugs Key Players in North America
- 5.3 North America Acute Ischemic Stroke Drugs Market Size by Type
- 5.4 North America Acute Ischemic Stroke Drugs Market Size by Application
6 Europe
- 6.1 Europe Acute Ischemic Stroke Drugs Market Size (2014-2019)
- 6.2 Acute Ischemic Stroke Drugs Key Players in Europe
- 6.3 Europe Acute Ischemic Stroke Drugs Market Size by Type
- 6.4 Europe Acute Ischemic Stroke Drugs Market Size by Application
7 China
- 7.1 China Acute Ischemic Stroke Drugs Market Size (2014-2019)
- 7.2 Acute Ischemic Stroke Drugs Key Players in China
- 7.3 China Acute Ischemic Stroke Drugs Market Size by Type
- 7.4 China Acute Ischemic Stroke Drugs Market Size by Application
8 Japan
- 8.1 Japan Acute Ischemic Stroke Drugs Market Size (2014-2019)
- 8.2 Acute Ischemic Stroke Drugs Key Players in Japan
- 8.3 Japan Acute Ischemic Stroke Drugs Market Size by Type
- 8.4 Japan Acute Ischemic Stroke Drugs Market Size by Application
9 International Players Profiles
- 9.1 Sanofi
- 9.1.1 Sanofi Company Details
- 9.1.2 Company Description and Business Overview
- 9.1.3 Acute Ischemic Stroke Drugs Introduction
- 9.1.4 Sanofi Revenue in Acute Ischemic Stroke Drugs Business (2014-2019))
- 9.1.5 Sanofi Recent Development
- 9.2 Biogen
- 9.2.1 Biogen Company Details
- 9.2.2 Company Description and Business Overview
- 9.2.3 Acute Ischemic Stroke Drugs Introduction
- 9.2.4 Biogen Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.2.5 Biogen Recent Development
- 9.3 Bayer
- 9.3.1 Bayer Company Details
- 9.3.2 Company Description and Business Overview
- 9.3.3 Acute Ischemic Stroke Drugs Introduction
- 9.3.4 Bayer Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.3.5 Bayer Recent Development
- 9.4 Pfizer
- 9.4.1 Pfizer Company Details
- 9.4.2 Company Description and Business Overview
- 9.4.3 Acute Ischemic Stroke Drugs Introduction
- 9.4.4 Pfizer Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.4.5 Pfizer Recent Development
- 9.5 Roche
- 9.5.1 Roche Company Details
- 9.5.2 Company Description and Business Overview
- 9.5.3 Acute Ischemic Stroke Drugs Introduction
- 9.5.4 Roche Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.5.5 Roche Recent Development
- 9.6 Boehringer Ingelheim
- 9.6.1 Boehringer Ingelheim Company Details
- 9.6.2 Company Description and Business Overview
- 9.6.3 Acute Ischemic Stroke Drugs Introduction
- 9.6.4 Boehringer Ingelheim Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.6.5 Boehringer Ingelheim Recent Development
- 9.7 Daiichi Sankyo
- 9.7.1 Daiichi Sankyo Company Details
- 9.7.2 Company Description and Business Overview
- 9.7.3 Acute Ischemic Stroke Drugs Introduction
- 9.7.4 Daiichi Sankyo Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.7.5 Daiichi Sankyo Recent Development
- 9.8 Bristol-Myers Squibb
- 9.8.1 Bristol-Myers Squibb Company Details
- 9.8.2 Company Description and Business Overview
- 9.8.3 Acute Ischemic Stroke Drugs Introduction
- 9.8.4 Bristol-Myers Squibb Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.8.5 Bristol-Myers Squibb Recent Development
- 9.9 Johnson&Johnson
- 9.9.1 Johnson&Johnson Company Details
- 9.9.2 Company Description and Business Overview
- 9.9.3 Acute Ischemic Stroke Drugs Introduction
- 9.9.4 Johnson&Johnson Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.9.5 Johnson&Johnson Recent Development
- 9.10 AstraZeneca
- 9.10.1 AstraZeneca Company Details
- 9.10.2 Company Description and Business Overview
- 9.10.3 Acute Ischemic Stroke Drugs Introduction
- 9.10.4 AstraZeneca Revenue in Acute Ischemic Stroke Drugs Business (2014-2019)
- 9.10.5 AstraZeneca Recent Development
- 9.11 ZZ Biotech
- 9.12 NoNO Inc
- 9.13 Athersys
- 9.14 SanBio
10 Market Forecast 2019-2025
- 10.1 Market Size Forecast by Product (2019-2025)
- 10.2 Market Size Forecast by Application (2019-2025)
- 10.3 Market Size Forecast by Regions
- 10.4 North America
- 10.5 Europe
- 10.6 China
- 10.7 Japan
11 Analyst's Viewpoints/Conclusions
12 Appendix
- 12.1 Research Methodology
- 12.1.1 Methodology/Research Approach
- 12.1.1.1 Research Programs/Design
- 12.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 12.1.2 Data Source
- 12.1.2.1 Secondary Sources
- 12.1.2.2 Primary Sources
- 12.1.1 Methodology/Research Approach
- 12.2 Disclaimer
Acute Ischemic Stroke (CIS), also known as Cerebral Infarction (CI), is due to the occlusion of the Cerebral artery caused by the Infarction of brain tissue, accompanied by damage to neurons, astrocytes, oligodendrocytes, is the modern society leading to death and disability of the most important central nervous system vascular events.
In 2018, the global Acute Ischemic Stroke Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Acute Ischemic Stroke Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Acute Ischemic Stroke Drugs development in North America, Europe, China and Japan.
The key players covered in this study
Sanofi
Biogen
Bayer
Pfizer
Roche
Boehringer Ingelheim
Daiichi Sankyo
Bristol-Myers Squibb
Johnson&Johnson
AstraZeneca
ZZ Biotech
NoNO Inc
Athersys
SanBio
Market segment by Type, the product can be split into
Tablet
Capsule
Other
Market segment by Application, split into
Hospitals
Diagnostic Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
The study objectives of this report are:
To analyze global Acute Ischemic Stroke Drugs status, future forecast, growth opportunity, key market and key players.
To present the Acute Ischemic Stroke Drugs development in North America, Europe, China and Japan.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Acute Ischemic Stroke Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.